<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002947</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065414</org_study_id>
    <secondary_id>YALE-HIC-9041</secondary_id>
    <secondary_id>NCI-G97-1154</secondary_id>
    <nct_id>NCT00002947</nct_id>
  </id_info>
  <brief_title>Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer</brief_title>
  <official_title>A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells.
      Giving radiation therapy in different ways may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating
      patients who have refractory cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose (MTD), toxic effects, and the preliminary
      antitumor activity of indium In 111 pentetreotide.

      OUTLINE: This is a dose escalation study. Patients receive indium In III pentetreotide
      (OctreoScan) IV on day 1. Imaging is conducted on days 3 and 6. Treatment continues weekly
      for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
      Cohorts of at least 3 patients receive escalating doses of OctreoScan until the maximum
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
      of 3 patients experience dose limiting toxicities. Patients are followed every 3 months for
      the first year, then every 6 months thereafter.

      PROJECTED ACCRUAL: Up to 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 1996</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Langerhans Cell Histiocytosis</condition>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Intraocular Melanoma</condition>
  <condition>Islet Cell Tumor</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Neoplastic Syndrome</condition>
  <condition>Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Pheochromocytoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 pentetreotide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven malignancy with no alternate treatments
        available Measurable or evaluable progressive disease Somatostatin receptors present on
        tumor and uptake demonstrated on diagnostic scan with OctreoScan

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count
        at least 1,500/mm3 Hepatic: Total bilirubin no greater than 2.0 mg/dL Renal: Creatinine
        clearance at least 40 mL/min Other: No active infections Not HIV positive No coexisting
        medical condition Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
        since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: Not
        specified Radiotherapy: At least 4 weeks since prior wide field radiation therapy Surgery:
        Recovery from prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R. Murren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2004</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>prolactin-producing pituitary tumor</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>childhood Langerhans cell histiocytosis</keyword>
  <keyword>metastatic pheochromocytoma</keyword>
  <keyword>recurrent pheochromocytoma</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III neuroendocrine carcinoma of the skin</keyword>
  <keyword>recurrent neuroendocrine carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

